Targeted Use of Placebo Effects Decreases Experimental Itch in Atopic Dermatitis Patients: A Randomized Controlled Trial
- PMID: 34784420
- DOI: 10.1002/cpt.2481
Targeted Use of Placebo Effects Decreases Experimental Itch in Atopic Dermatitis Patients: A Randomized Controlled Trial
Comment in
-
Response to "Targeted Use of Placebo Effects Decreases Experimental Itch in Atopic Dermatitis Patients: A Randomized Controlled Trial".Clin Pharmacol Ther. 2022 Mar;111(3):541. doi: 10.1002/cpt.2483. Epub 2021 Nov 17. Clin Pharmacol Ther. 2022. PMID: 34787923 No abstract available.
Comment on
-
Targeted Use of Placebo Effects Decreases Experimental Itch in Atopic Dermatitis Patients: A Randomized Controlled Trial.Clin Pharmacol Ther. 2021 Aug;110(2):486-497. doi: 10.1002/cpt.2276. Epub 2021 May 25. Clin Pharmacol Ther. 2021. PMID: 33894061 Clinical Trial.
References
-
- Sölle, A., Worm, M., Benedetti, F., Sabine Bartholomäus, T., Schwender-Groen, L. & Klinger, R. Targeted use of placebo effects decreases experimental itch in atopic dermatitis patients: a randomized controlled trial. Clin. Pharmacol. Ther. 110, 486-497 (2021).
-
- Narla, S. & Silverberg, J.I. The role of environmental exposures in atopic dermatitis. Curr. All. Asthma Rep. 20, 1-18 (2020).
-
- Geyfman, M. et al. Brain and muscle Arnt-like protein-1 (BMAL1) controls circadian cell proliferation and susceptibility to UVB-induced DNA damage in the epidermis. Proc. Natl Acad. Sci. USA 109, 11758-11763 (2012).
-
- Vaughn, A.R., Clark, A.K., Sivamani, R.K. & Shi, V.Y. Circadian rhythm in atopic dermatitis-Pathophysiology and implications for chronotherapy. Pediatr. Dermatol. 35, 152-157 (2018).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials